Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease
28 de outubro de 2019 atualizado por: Gad Alon, University of Maryland, Baltimore
Can Transcranial Direct Current Stimulation (tDCS)Modulate Protective Stepping and Gait Performance of People With Parkinson's Disease
The use of low level electrical stimulation when applied over the head, also called transcranial direct current stimulation (tDCS), is being tested by several groups of researchers to see if tDCS can improve movements of persons with damage to the brain.
The safety and potential benefits of tDCS to children or adults patients who are paralyzed because of brain damage are reported in the medical literature.
In addition, some patients with Parkinson's disease (PD) experience improvement in memory and report better use of the hand after tDCS.
The treatment requires putting electrodes (pads) over the head and sending very small amount of electrical current that the patient may feel as "little tingling".
Application of tDCS takes 20 min.
In this study we wish to test if tDCS application can improve stepping and walking ability of subjects with PD and if the improvement is the same as when walking on treadmill.
We plan to test the subject's ability to step when pulled by a laboratory testing system and also test his/her walking ability.
There will be 3 sessions 7 days apart.
In the first session the subject will be tested then treated for 20 min with tDCS and then tested again.
In the second session the subject will be tested then walk on a treadmill for 20 min then tested again.
In the third session the subject will be tested then walk on the treadmill for 20 min while receiving also tDCS and tested one last time at the end of the session.
Each session will take between 2 and 3 hours.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Recent advances in non-invasive electrical stimulation technology including transcranial direct current stimulation (tDCS) have provided novel and low risk options to rehabilitate the impaired ability of the central nervous system (CNS) to process sensorimotor information.
Furthermore, tDCS appears to enhance CNS connectivity and there is preliminary evidence indicating that patients with Parkinson's Disease (PD) may experience improvement in working memory, the Unified Parkinson's Disease Rating Scale, simple reaction time and the Purdue Pegboard test.
tDCS is inexpensive, portable and available for repeated home use.
It may provide long-lasting enhancement of cortical activity in part because tDCS is easy to administer frequently and to combine it with other rehabilitation approaches including posture and gait training.
However to date, no study has examined quantitatively the effects of tDCS on posture control and walking ability in patients with PD.
As a first step we plan to identify the immediate effects of tDCS, as well as the added value of tDCS to treadmill exercise training, to improve posture and gait of individuals with PD.
Tipo de estudo
Intervencional
Inscrição (Real)
10
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- PTRS Research Lab
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 85 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Diagnosis of adult onset of PD
- A history of freezing of gait (FOG) as evidence by clinical assessment
- A stable regimen of anti-parkinsonian medications
- Ability to walk at least 10m without assistance
- Ability to walk on a treadmill for 20 minutes
- Personal weight of less than 500 Lb (because the suspension harness over the treadmill is limited to 500 Lb
- Stage 3 of the Hoehn and Yahr disability scale
- A score of >24 on the Mini Mental State Examination
Exclusion Criteria:
- Evidence of any clinically significant functional impairment related to cardiovascular, pulmonary, metabolic, other neurologic or musculoskeletal disease criterial that would preclude participation in training
- Any medical condition that might require other medical or surgical treatment during the study period
- A history of brain surgery or placement of a deep brain stimulator
- Dyskinesias > grade 2 on the Unified Parkinson's Disease Rating Scale (UPDRS)
- Any uncorrected vision or hearing problems that may limit daily activities or communication
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Single Group
10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
|
We will follow the procedure described by several investigators as safe and effective.
The participant will sit on a standard chair.
Two commercially available surface electrodes will be embedded in an elastic head cup.
Each electrode will be covered with a water soaked absorbent fabric.
One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas.
One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region.
The electrodes will be connected via 2 leads to a battery powered direct current stimulator.
The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stride Length
Prazo: Data collection occurred before and immediately after each training session
|
Stride Length was measured in centimeters
|
Data collection occurred before and immediately after each training session
|
|
Gait Velocity
Prazo: Data collection occurred before and immediately after each training session
|
Gait Velocity was measured in meters per second
|
Data collection occurred before and immediately after each training session
|
|
Cadence
Prazo: Data collection occurred before and immediately after each training session
|
Cadence was measured in steps per minute
|
Data collection occurred before and immediately after each training session
|
|
Number of Steps to Regain Balance
Prazo: Data collection occurred before and immediately after each training session
|
Steps to regain balance were measured by the number of steps needed to recover standing balance.
The steps were counted using a custom software of the motion capture system.
|
Data collection occurred before and immediately after each training session
|
|
First Step Length
Prazo: Data collection occurred before and immediately after each training session
|
First step length was measured in meters from the starting position of the foot to the maximum displacement of the foot after the first step.
Measurements were taken separately for forward and backward first step.
|
Data collection occurred before and immediately after each training session
|
|
First Step Velocity
Prazo: Data collection occurred before and immediately after each training session
|
First step velocity was measured in meters per second
|
Data collection occurred before and immediately after each training session
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Gad Alon, PhD, PT, University of Maryland, Baltimore
- Investigador principal: Mark W Rogers, PhD, PT, University of Maryland, Baltimore
- Investigador principal: Lisa Shulman, MD, Univeristy of Maryland, Baltimore
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de janeiro de 2010
Conclusão Primária (Real)
1 de junho de 2011
Conclusão do estudo (Real)
1 de junho de 2011
Datas de inscrição no estudo
Enviado pela primeira vez
19 de março de 2010
Enviado pela primeira vez que atendeu aos critérios de CQ
8 de abril de 2010
Primeira postagem (Estimativa)
9 de abril de 2010
Atualizações de registro de estudo
Última Atualização Postada (Real)
30 de outubro de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
28 de outubro de 2019
Última verificação
1 de outubro de 2019
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HP-00040670
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Cranial Electric Stimulation (CES)
-
Massachusetts General HospitalFisher Wallace Labs, LLCConcluídoTranstorno Depressivo MaiorEstados Unidos